Drug Trial Radar · NCT01925209
Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients
Last checked: Nov 19, 2026Latest source record: Aug 11, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
251
Actual
Start
Sep 26, 2013
Primary completion
Jan 6, 2016
Study completion Jan 6, 2016
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Aug 19, 2013
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 36 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study evaluated the efficacy, safety and tolerability of multiple doses of bimagrumab/BYM338 vs placebo, when administered intravenously (i.v.), on physical function, muscle strength, and mobility in patients with sporadic inclusion body myositis (sIBM).
Conditions
- Sporadic Inclusion Body Myositis
Interventions
BYM338/bimagrumabDrug
BYM338, a 150 mg/mL concentrate for solution for i.v. infusion, was provided in colorless glass vials with a rubber stopper and aluminum flip-off caps.
PlaceboDrug
Matching placebo to BYM338 was provided in colorless glass vials with a rubber stopper and aluminum flip-off caps.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in 6 Minute Walking Distance (6MWD) Test at Week 52Time frame: Baseline, Week 52
Locations
38 sites in 10 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Phoenix, Arizona
Novartis Investigative Site
Orange, California
Novartis Investigative Site
Sacramento, California
Novartis Investigative Site
Miami, Florida
Novartis Investigative Site
Kansas City, Kansas
Novartis Investigative Site
Baltimore, Maryland
Novartis Investigative Site
Boston, Massachusetts
Novartis Investigative Site
Boston, Massachusetts
Novartis Investigative Site
Columbus, Ohio
Novartis Investigative Site
Portland, Oregon
Novartis Investigative Site
Dallas, Texas
Novartis Investigative Site
Houston, Texas
Novartis Investigative Site
St Leonards, New South Wales, Australia
Novartis Investigative Site
Cauldfield, Victoria, Australia
Novartis Investigative Site
Nedlands, Western Australia, Australia
Novartis Investigative Site
Brussels, Belgium
Novartis Investigative Site
Edegem, Belgium
Novartis Investigative Site
Ghent, Belgium
Novartis Investigative Site
Copenhagen, Denmark
Novartis Investigative Site
Paris, France
Novartis Investigative Site
Brescia, BS, Italy
Novartis Investigative Site
Rome, Lazio, Italy
Novartis Investigative Site
Messina, ME, Italy
Novartis Investigative Site
Milan, MI, Italy
Novartis Investigative Site
Padova, PD, Italy
Novartis Investigative Site
Nagoya, Aichi-ken, Japan
Novartis Investigative Site
Kumamoto, Kumamoto, Japan
Novartis Investigative Site
Sendai, Miyagi, Japan
Novartis Investigative Site
Osaka, Osaka, Japan
Novartis Investigative Site
Tokushima, Tokushima, Japan
Novartis Investigative Site
Kodaira, Tokyo, Japan
Novartis Investigative Site
Wakayama, Wakayama, Japan
Novartis Investigative Site
Amsterdam, Netherlands
Novartis Investigative Site
Leiden, Netherlands
Novartis Investigative Site
Zurich, Switzerland
Novartis Investigative Site
London, United Kingdom
Novartis Investigative Site
Newcastle upon Tyne, United Kingdom
Novartis Investigative Site
Salford, Manchester, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.